PERSPECTA

News from every angle

Back to headlines

Eli Lilly Terminates Licensing Agreement with Rigel for Ocadusertib

Pharmaceutical company Eli Lilly has ended its license agreement with Rigel Pharmaceuticals concerning the drug ocadusertib.

21 Apr, 21:36 — 21 Apr, 21:36
PostShare

Sources

Showing 1 of 1 sources